This is unpublished
Dr. Ruane Barnabas
November 19, 2021

Single dose HPV vaccine

Results of randomized controlled trial in Kenya bring new energy to eliminate cervical cancer worldwide.
Scroll for more
arrow icon
Back to top

A randomized controlled trial of 2,275 women in Kenya showed that a single dose of the human papillomavirus (HPV) vaccine was highly effective. The current standard for women is a three-dose regimen.

“The single-dose vaccine was highly effective at 18 months for HPV vaccination,” said Ruanne Barnabas, principal investigator of the trial and a professor of medicine (Allergy and Infectious Diseases) and global health. “The single-dose efficacy was the same as multiple doses.”

This news could greatly hasten the pace of vaccinations and brings renewed energy to the push to make cervical cancer the first cancer to be wiped out globally.


Read the full story from UW Medicine Newsroom.